Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $5
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $4 to $5.
Stocks · News reference
Treace Medical Presents 5-Year ALIGN3D Data Showing 0.8% Recurrence Rate Alongside MTA3D And SPRINT Clinical Results At AOFAS 2026
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Treace Medical Concepts shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance.
8-K filing — TREACE MEDICAL CONCEPTS, INC. (TMCI)
Filed: 2026-08-07 AccNo: 0001630627-26-000017 Size: 726 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits